OPKO Health, Inc.

OPK

HealthcareMedical - Diagnostics & ResearchNASDAQ

$1.14

Market Cap: $860.81M

OPKO Health, Inc. (OPK) Valuation Summary

Updated May 10, 2026 19:24

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	—	N/A	—
Revenue DCF 10Y	$0.01 – $0.73	$0.15	-86.9%
▸ Trading Multiples
EV/Revenue	$1.18 – $6.46	$3.90	+242.4%

Valuation History

DCF Analysis

OPKO Health, Inc. (OPK) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.15

Market Price

$1.14

Upside / Downside

-86.9%

Verdict

Overvalued

Using a Revenue DCF model with operating margin convergence from -36.1% to a target of 13.2% over 5 years, discounted at a WACC of 10.4%, OPKO Health, Inc. (OPK) has an intrinsic value of $0.15 per share (range: $0.01 – $0.73).

Key Assumptions

Current Operating Margin

-36.1%

Target Operating Margin

13.2%

WACC

10.4%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.3%

Target CapEx/Rev

16.9%

D&A/Revenue

11.3%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	538	-11.4%	-26.2%	-141	-141	61	(20)	-21	-79	-76
2027	568	5.6%	-16.4%	-93	-93	64	(30)	5	-64	-55
2028	609	7.3%	-6.5%	-40	-40	69	(41)	7	-19	-15
2029	650	6.7%	3.3%	22	17	73	(53)	7	30	21
2030	690	6.2%	13.2%	91	72	78	(66)	7	76	49
2031	621	-10.0%	13.2%	82	65	70	(69)	-12	78	45
2032	559	-10.0%	13.2%	74	58	63	(70)	-11	62	33
2033	503	-10.0%	13.2%	66	52	57	(70)	-10	48	23
2034	474	-5.8%	13.2%	62	49	53	(73)	-5	35	15
2035	467	-1.4%	13.2%	62	49	53	(79)	-1	24	9

Enterprise Value Bridge

Sum of PV(FCFF)50

Terminal Value (Gordon Growth at 3.0%)329

PV of Terminal Value129

Enterprise Value178

(–) Net Debt65

Equity Value114

(÷) Shares Outstanding766

Fair Value per Share$0.15

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
8.4%	$-0	$0	$0	$1	$1
9.4%	$-0	$0	$0	$0	$1
10.4%	$-0	$-0	$0	$0	$0
11.4%	$-0	$-0	$0	$0	$0
12.4%	$-0	$-0	$0	$0	$0

Current price: $1.14. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 17.4% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$3.90

Market Price

$1.14

Upside / Downside

+242.4%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), OPKO Health, Inc. (OPK) has a fair value of $3.90 based on 7 comparable companies in the Medical - Diagnostics & Research industry.

EV/Revenue Valuation — Medical - Diagnostics & Research

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
OPKO Health, Inc.OPK	873	1.5x	1.7x
Nektar TherapeuticsNKTR	1,662	32.5x	43.3x
Tandem Diabetes Care, Inc.TNDM	1,265	1.6x	1.5x
Pacira BioSciences, Inc.PCRX	930	1.7x	1.6x
Xencor, Inc.XNCR	903	8.3x	11.7x
Personalis, Inc.PSNL	532	5.7x	6.2x
Claritev CorporationCTEV	458	5.3x	5.4x
LifeMD, Inc.LFMD	231	1.0x	1.0x
Industry Median		5.3x	5.4x
(*) Revenue		607	538
= Enterprise Value		3,189	2,917
(-) Net Debt		65	65
Equity Value		3,125	2,852
(/) Outstanding shares		766	766
Fair Price		$4	$4

Selected Fair Value (avg of trailing + forward)

$3.90

+242.4%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

—

N/A

—

Revenue DCF 10Y

$0.01 – $0.73

$0.15

-86.9%

▸ Trading Multiples

EV/Revenue

$1.18 – $6.46

$3.90

+242.4%

DCF Analysis

OPKO Health, Inc. (OPK) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.15

Market Price

$1.14

Upside / Downside

-86.9%

Verdict

Overvalued

Key Assumptions

Current Operating Margin

-36.1%

Target Operating Margin

13.2%

WACC

10.4%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.3%

Target CapEx/Rev

16.9%

D&A/Revenue

11.3%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	538	-11.4%	-26.2%	-141	-141	61	(20)	-21	-79	-76
2027	568	5.6%	-16.4%	-93	-93	64	(30)	5	-64	-55
2028	609	7.3%	-6.5%	-40	-40	69	(41)	7	-19	-15
2029	650	6.7%	3.3%	22	17	73	(53)	7	30	21
2030	690	6.2%	13.2%	91	72	78	(66)	7	76	49
2031	621	-10.0%	13.2%	82	65	70	(69)	-12	78	45
2032	559	-10.0%	13.2%	74	58	63	(70)	-11	62	33
2033	503	-10.0%	13.2%	66	52	57	(70)	-10	48	23
2034	474	-5.8%	13.2%	62	49	53	(73)	-5	35	15
2035	467	-1.4%	13.2%	62	49	53	(79)	-1	24	9

Enterprise Value Bridge

Sum of PV(FCFF)50

Terminal Value (Gordon Growth at 3.0%)329

PV of Terminal Value129

Enterprise Value178

(–) Net Debt65

Equity Value114

(÷) Shares Outstanding766

Fair Value per Share$0.15

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
8.4%	$-0	$0	$0	$1	$1
9.4%	$-0	$0	$0	$0	$1
10.4%	$-0	$-0	$0	$0	$0
11.4%	$-0	$-0	$0	$0	$0
12.4%	$-0	$-0	$0	$0	$0

Current price: $1.14. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 17.4% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$3.90

Market Price

$1.14

Upside / Downside

+242.4%

Verdict

Undervalued

EV/Revenue Valuation — Medical - Diagnostics & Research

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
OPKO Health, Inc.OPK	873	1.5x	1.7x
Nektar TherapeuticsNKTR	1,662	32.5x	43.3x
Tandem Diabetes Care, Inc.TNDM	1,265	1.6x	1.5x
Pacira BioSciences, Inc.PCRX	930	1.7x	1.6x
Xencor, Inc.XNCR	903	8.3x	11.7x
Personalis, Inc.PSNL	532	5.7x	6.2x
Claritev CorporationCTEV	458	5.3x	5.4x
LifeMD, Inc.LFMD	231	1.0x	1.0x
Industry Median		5.3x	5.4x
(*) Revenue		607	538
= Enterprise Value		3,189	2,917
(-) Net Debt		65	65
Equity Value		3,125	2,852
(/) Outstanding shares		766	766
Fair Price		$4	$4

Selected Fair Value (avg of trailing + forward)

$3.90

+242.4%